Pharmaceutical Executive
William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.
Joe DiMasi
Advertisement
Articles by Joe DiMasi
Advertisement
Latest Updated Articles
Talkback from Tufts: Defending R&D CostsFebruary 13th 2012
Advertisement
Advertisement
Trending on PharmExec
1
The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff
2
President Trump Planning to Fire FDA Commissioner Marty Makary: Report
3
Marty Makary Out as FDA Commissioner: Report
4
From Consulting to Venture Capital: A Q&A with Gibb Witham, President of Hack The Box
5